Clinical trials: Lung Cancer, completed
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
SARS-CoV-2 Donor-Recipient Immunity Transfer
This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed.
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04666025
- Testing
- Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer, Breast Cancer
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
- Trial name
- NCT02005458
- Testing
- YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- Where
- 12 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer
PD-1 antibody has been approved as second line therapy for driven mutation negative non-small cell lung cancer, but overall response rate is only between 15-20%.
- Trial name
- NCT03958097
- Testing
- NK cell and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Non Squamous Non Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
- Trial name
- Spruce (NCT01829113)
- Testing
- OGX-427
- Where
- 16 sites in United States
- Volunteers
- 155 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
A Feasibility Study of Oral Adjuvant Chemotherapy With S-1
The investigators confirm the feasibility of 1-year administration of oral fluoropyrimidine S-1 as an adjuvant chemotherapy for the patient who received complete resection of non-small cell lung cancer.
- Trial name
- NCT01459185
- Testing
- S-1
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- Tomoshi Tsuchiya
Breast Cancer, Breast Neoplasm
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is…
- Conditions
- Breast Cancer, Breast Neoplasm, Artificial Intelligence, Ultrasonography
- Trial name
- NCT06255808
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group
Pulmonary Cancer
Quantification of microRNAs in Diagnosis of Pulmonary Nodules
One of the main challenges of thoracic oncology lies in earlier diagnosis of lung cancer to improve survival rate, wich is about 15% at 5 years. This poor prognosis is often linked to late diagnosis.
- Trial name
- miR-Nod (NCT03293433)
- Testing
- Blood punction
- Where
- 2 sites in France
- Volunteers
- 103 people
- Sponsor
- University Hospital, Toulouse
Lung Cancer
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00407550
- Testing
- gemcitabine HCL, pemetrexed disodium
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Lung Cancer
NK Cell Activity in Smokers Screened for Lung Cancer
Objectives: To examine whether NK cell activity associates with two confirmed risk factors: (1) presence of indeterminate lung nodule(s) and (2) smoking exposure after controlling for potential confounders, including age, gender…
- Trial name
- NCT02840578
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- University of Southern California
Lung Cancer, Non-Small Cell
NSCLC Burden of Illness Study
The aim of this observational study is to identify and quantify the humanistic and economic burden of illness of patients with complete resection (no residual disease) of stage IB-IIIA NSCLC in three European countries (France…
- Trial name
- LuCaBIS (NCT01772225)
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
- Trial name
- NCT00374140
- Testing
- RAD001 (everolimus)
- Where
- 19 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ahmad Tarhini
Non Small Cell Lung Cancer
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
The purpose of this randomized phase II trial is to determine the clinical feasibility - in terms of patients without dose limiting toxicities or premature treatment withdrawal or death - of the combination of Cisplatin and…
- Trial name
- NCT00349089
- Testing
- Pemetrexed, Cisplatin, Vinorelbine
- Where
- 14 sites in Belgium, Germany and 1 more
- Volunteers
- 132 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH
Non-small Cell Lung Cancer Metastatic
Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced NSCLC.
- Trial name
- NCT02843815
- Testing
- Cryosurgery, NK Immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Non-small Cell Lung Cancer
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00050674
- Testing
- Filgrastim-SD/01
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Schwartzberg, Lee, M.D.
Carcinoma, Non-Small-Cell Lung, Bone Metastases
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)
Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC). They most often occur during disease progression. It is thought that more than half of the patients with bone metastases will have at least 1 skeletal-related…
- Trial name
- DENIVOS (NCT03669523)
- Testing
- Denosumab-nivolumab combination
- Where
- 27 sites in France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy.
- Trial name
- MERIT (NCT02774278)
- Testing
- Erlotinib
- Where
- 29 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 264 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
This is a phase 2 multicenter, open label, randomized study of AMG 951 (rhApo2L/TRAIL) in subjects with previously untreated stage IIIb/IV NSCLC treated with chemotherapy with or without bevacizumab.
- Trial name
- NCT00508625
- Testing
- AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin
- Volunteers
- 213 people
- Sponsor
- Amgen